VIVEbiotech Expands Lentiviral Vector Manufacturing Capabilities with EvoLVcell

Transfection-free stable producer cell line (SCL) offers easy scalability, reduction of cost of goods (COGs), improve vector quality, and low batch variability.

San Sebastián, Spain, May 11 2026 — VIVEbiotech, a leading lentiviral vector (LVV) Contract Development and Manufacturing Organization (CDMO), today announced the addition of EvoLVcell to its catalogue of LVV-manufacturing products, representing a cost-effective, transfection-free alternative to its existing transient transfection process. The thoroughly characterized, inducible, monoclonal lentiviral packaging cell line (PCL) derisks stable producer cell line (SCL) generation by incorporating the therapeutic transgene that typically would be transfected together with the helper plasmids. This SCL platform generation enables VIVEbiotech to get a prototype cell line in three months.

EvoLVcell is a SCL generation platform designed to reduce batch‑to‑batch variability, improve vector quality, and provide a more predictable long‑term production strategy for LVVs. The fully integrated platform requires only the addition of a developer’s transgenic element to the fully characterized monoclonal PCL, avoiding transfection – simplifying the manufacturing workflow, improving long-term predictability, and reducing reliance on plasmid and transfection reagent supply chains.

EvoLVcell reduces variability and produces fewer impurities, of particular importance to gene therapeutics¹. At the same time, the platform's extensive characterization enables rapid yield assessment through a rapid proof-of-concept, allowing developers to reach a clear a go/no-go inflection point in just three months. High throughput clone screening lets VIVEbiotech to pick the best performance clone in terms of viral titer, stability, and transgene integrity. Also, the resulting clone can be adapted from adherent to suspension. 

“Achieving cost efficiency and high reproducibility is essential for the scalable production of lentiviral vectors and for expanding patient access. Stable producer cell lines provide a reliable and scalable manufacturing platform to support this goal,” said Andrés Lamsfus-Calle, PhD, Product Development Manager at VIVEbiotech. “EvoLVcell provides a powerful alternative to transient transfection — one that de‑risks production, improves quality, and supports long‑term scalability for our partners.”

The EvoLVcell platform is initially available for VSV‑G pseudotyped lentiviral vectors, the most widely used LVV envelope. EvoLVcell will complement VIVEbiotech’s established transient transfection, offering developers more flexibility depending on program needs.

Other features include:

·         Helper genes remain fully silent during cell expansion, limiting potential toxicity and cell instability.

·         Expression activated with low concentrations of doxycycline, minimizing risk of residual inducer in the final product.

·         Demonstrates strong repression when off and high titers when on, important to maintain cell stability and transgene integrity.

·         No requirement of plasmids and transfection agents, reducing considerably COGs.

·         Manufacturing flexibility. Adaptable to adherent or suspension platforms.

·         Improvement in vector quality, decreasing total amount of contaminants associated with the manufacturing process.

“EvoLVcell reflects years of purpose-built LVV manufacturing development based on the unrivalled expertise of our team,” said Marie Fertin, Chief of Custom Solution and Process Development Officer of VIVEbiotech. “We are committed to providing the cost-effective and consistent options for our partners need in order to reliably reach commercial scale.”

About VIVEbiotech

VIVEbiotech is a Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral vectors for gene and cell therapy. Founded in 2015, VIVEbiotech operates under EMA and FDA standards, serving over 55 biotech companies globally. The company focuses on scalable, high-yield manufacturing processes and cutting-edge technologies. With expertise in both ex-vivo and in-vivo applications, VIVEbiotech supports the development and commercialization of therapies for cancers and rare diseases, among others. For more information about VIVEbiotech, please visit vivebiotech.com or follow us on LinkedIn.